Every Form 4 that Core Laboratories Inc. (CLB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLB filings page.
Core Laboratories Inc. (CLB) reported that Mark Damian Tattoli, SVP, Gen Counsel & Secretary, had a derivative exercise/conversion involving 700 restricted shares, reported as disposed, and acquired 700 common shares on October 1, 2026. On the same date, 276 common shares were delivered or withheld for payment of exercise price or tax liability; the reported price was $9.76 per share. No Rule 10b5-1 plan is reported.
The restricted shares vest annually over six years on the grant anniversary, subject to continuous service. Reported holdings following the transaction included 250 restricted shares, plus indirect common-stock holdings of 20 shares in a custodial account and 1,695 shares in a 401 (k) Plan.
Core Laboratories Inc. (CLB) reported that its CAO & Treasurer, Sow Hang Teo, disposed of 250 restricted shares in an exercise/conversion and acquired 250 common shares on October 1, 2026. He also reported 99 common shares delivered or withheld for payment of exercise price or tax liability; the reported price was $9.76 per share. After the derivative transaction, 6,000 restricted shares were reported, including multiple grants. The awards vest annually over six years, subject to continuous service on each vesting date. No Rule 10b5-1 plan is reported.
Core Laboratories Inc. reported that Chairman and CEO Bruno Lawrence purchased 5,000 shares of common stock on July 31, 2026 at $10.78 per share, described as a purchase in open market or private transaction. After this trade, his directly held stake totaled 262,438 shares.
Core Laboratories CAO & Treasurer Teo Sow Hang exercised 440 Restricted Shares into Common Stock on August 1, 2026, and disposed of 198 Common shares at $10.64 per share to pay the exercise price or tax liability. The Restricted Shares vest annually over six years and reflect multiple grants.
Core Laboratories executive Mark Damian Tattoli exercised restricted share awards for 250 underlying common shares at $0 on 1 August 2026. The related restricted shares were canceled and 99 common shares were disposed of at $10.64 per share as payment of exercise price or tax liability. Following these transactions he holds 950 restricted shares directly, plus indirect common stock positions of 20 shares in a custodial account and 1,694.8420 shares in a 401 (k) Plan. These transactions were not reported under a Rule 10b5-1 trading plan.
Core Laboratories executive Mark Damian Tattoli, SVP, General Counsel & Secretary, exercised a restricted share award that delivered 250 shares of Common Stock on May 1, 2026. To cover tax obligations, 97 shares were disposed of at $14.07 per share, leaving 27,513.621 directly held shares.
He also holds shares indirectly, including 1,694.842 shares through a 401(k) plan and 20 shares in a custodial account. The filing notes multiple restricted share grants vesting annually over six years, contingent on continued service.
Core Laboratories director Katherine Murray reported equity compensation activity. She received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to issuance terms and an elective deferral. Separately, 8,069 Restricted Shares completed a prior one-year vesting period and converted into 8,069 shares of Common Stock at no cost, bringing her directly held Common Stock to 29,290 shares.
Core Laboratories director Curt Anastasio reported routine equity compensation activity involving restricted shares and common stock. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance.
These Restricted Shares are subject to a deferral election under Treasury Regulation 1.409A-2, with vested shares to be distributed as common stock following his separation of service from the Board. He also exercised 8,069 Restricted Shares that had vested after a one-year vesting period ending April 1, 2026, receiving 8,069 shares of Common Stock and bringing his directly held common shares to 23,805. The filing shows acquisitions and exercises only, with no open-market buying or selling.
Core Laboratories Inc. director Harvey Robert Klingensmith reported equity compensation activity in company stock. He received a grant of 7,895 Restricted Shares on April 1, 2026 at a price of $0.00 per share. According to the terms, these Restricted Shares will vest at the end of a one-year vesting period on April 1, 2027, and are subject to a deferral election, with vested shares distributed as common stock after his separation of service from the Board. On the same date, 8,069 previously granted Restricted Shares vested at the end of their one-year vesting period and were converted into 8,069 shares of Common Stock at $0.00 per share. Following these transactions, Klingensmith directly holds 50,031 shares of Core Laboratories common stock.
Core Laboratories director Temeng Kwaku reported equity compensation and an option-style exercise. On April 1, 2026, he received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to the terms of issuance and a deferral election under Treasury Regulation 1.409A-2.
The filing also shows 8,069 Restricted Shares vested after a one-year period ending April 1, 2026 and were exercised into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, Kwaku directly holds 33,597 shares of Core Laboratories Common Stock.
Core Laboratories Inc. director Robert F. Martinovich reported equity-based compensation activity. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance and any deferral election.
Separately, 8,069 Restricted Shares vested at the end of a prior one-year vesting period on April 1, 2026 and were exercised into 8,069 shares of Common Stock, which he now holds directly. The filing shows only awards and an option-style conversion of restricted equity into common stock, with no open-market purchases or sales.
Core Laboratories director Martha Z. Carnes reported equity compensation activity involving restricted shares and common stock. She received a grant of 7,895 Restricted Shares on April 1, 2026, which will vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance.
On the same date, 8,069 previously granted Restricted Shares completed their one-year vesting period ending April 1, 2026 and were converted into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, she directly holds 54,397 shares of Core Laboratories common stock.
Core Laboratories Inc. granted SVP, General Counsel and Secretary Mark Damian Tattoli 33,490 performance shares on February 12, 2026. These are derivative equity awards with no cash exercise price.
The award is tied to a three-year performance period from January 1, 2026 through December 31, 2028. Vesting, if any, occurs on December 31, 2028 and depends on the company’s Return on Invested Capital versus a Bloomberg Peer Group, ranging from 50% to 175% of the target award, with higher vesting for stronger relative performance and a reduction if total shareholder return over the period is negative.
Core Laboratories Inc. granted SVP Gwendolyn Gresham 33,490 performance shares on February 12, 2026 at an exercise price of $0. These shares relate to a three-year performance period from January 1, 2026 to December 31, 2028.
The award will vest, if at all, on December 31, 2028 based on the company’s Return on Invested Capital versus the Bloomberg Peer Group. Payout levels range from 50% to 175% of the target award, with straight-line interpolation and a reduction if total shareholder return is negative.
Core Laboratories Inc. reported an insider equity award to its SVP & CFO, Christopher Scott Hill. On February 12, 2026, he received a grant of 70,008 performance share units at an exercise price of $0, held as a direct derivative position.
The award is tied to a three-year performance period from January 1, 2026 through December 31, 2028. Vesting on December 31, 2028 depends on the company’s Return on Invested Capital versus a Bloomberg Peer Group, with payout ranging from 50% to 175% of the target shares and straight-line interpolation between thresholds. Any portion above 100% is cut in half if total shareholder return over the period is negative.
The filing also clarifies that Hill has indirect beneficial ownership of 59 common shares held in the company’s 401(k) plan, correcting an omission from a prior Form 4.
Core Laboratories Inc. Chairman and CEO Bruno Lawrence received an award of 204,340 performance share units on February 12, 2026. These derivative securities have an exercise price of $0 and are structured to vest based on a three-year performance period from January 1, 2026 through December 31, 2028.
The shares, which are held directly, will vest, if at all, on December 31, 2028 depending on the company’s Return on Invested Capital ranking within the Bloomberg Peer Group. Vesting ranges from 50% to 175% of the award, with amounts above 100% reduced by half if absolute total shareholder return over the performance period is negative.
Core Laboratories Inc. granted Chief Accounting Officer and Treasurer Teo Sow Hang 7,526 performance share units on February 12, 2026 at an exercise price of $0 per unit. These derivative awards relate to an equal number of underlying shares of common stock and are held directly.
The award is structured around a three-year performance period from January 1, 2026 through December 31, 2028 and will vest on December 31, 2028, assuming continued employment or qualifying death or disability. Payout depends on Return on Invested Capital versus the Bloomberg Peer Group: 100% of the target amount vests at the top 55th percentile of ROIC, and up to 200% can vest at or above the 85th percentile, with straight-line interpolation between those points.
Core Laboratories Inc. reported an insider equity transaction by its Senior Vice President, General Counsel & Secretary on December 31, 2025. A previously granted performance-based restricted share award vested at 116.5% of the target level, resulting in the delivery of 24,952 shares of common stock after the company finished in the 68th percentile for return on invested capital versus its Bloomberg Peer Group for the performance period ending December 31, 2025.
On the same date, 14,310 shares of common stock at a price of $16.03 were withheld or disposed of in a transaction coded "F", typically associated with tax withholding, and the reporting person’s directly held common stock position increased to 41,670.621 shares, with additional small indirect holdings through a custodial account and a 401(k) plan.
Core Laboratories Inc. reported an equity transaction by a senior vice president involving vested performance-based stock awards. On December 31, 2025, 24,952 performance shares with a stated exercise price of $0 were converted into common stock, reflecting the vesting of a February 2023 restricted performance share grant. The company finished in the 68th percentile for return on invested capital within the Bloomberg Peer Group, so the award vested at 116.5% of the target level. On the same date, 19,301 common shares were disposed of in a transaction coded “F” at $16.03 per share, typically indicating shares withheld or sold to cover tax obligations.
Core Laboratories Inc. reported an insider equity transaction by its SVP & CFO. On December 31, 2025, the officer acquired 61,417 shares of common stock at an exercise price of $0 through the vesting of performance-based restricted shares. On the same date, 32,152 shares were disposed of at $16.03 per share, typically reflecting shares withheld to cover taxes associated with the vesting.
The filing shows the officer directly beneficially owning 142,354 shares of Core Laboratories common stock following these transactions. The performance shares were originally granted in February 2023. The company finished in the 68th percentile of return on invested capital relative to its Bloomberg Peer Group for the performance period ending December 31, 2025, leading to vesting at 116.5% of the target award level.
Core Laboratories Inc. (CLB) reported insider equity activity by its Chairman and CEO dated 12/31/2025. The filing shows the vesting and conversion of 180,722 performance shares into common stock at an exercise price of $0, reported under transaction code M, and the disposition of 112,681 common shares at a price of $16.03 per share, reported under code F. Following these transactions, the filing lists direct beneficial ownership amounts of 370,119 shares and 257,438 shares after the respective entries.
The performance shares were originally granted as restricted performance shares in February 2023. The company finished in the 68th percentile for return on invested capital versus a Bloomberg-defined peer group for the performance period ending December 31, 2025. As a result, the performance criteria were satisfied at 116.5% of the target award level, and that number of shares vested on December 31, 2025.
Core Laboratories Inc. CAO & Treasurer reported equity transactions in company stock dated 12/01/2025. The officer had 864 restricted shares convert into common stock at a price of $0, increasing directly held common shares to 8,765.334.
To cover obligations associated with this vesting, 340 common shares were disposed of at $15.39 per share, leaving the officer with 8,425.334 shares before the conversion and 8,765.334 afterward. The filing also shows 6,690 restricted shares remaining, from multiple grants that vest annually over six years as long as the officer continues in service.